TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32800064

Group type: EXPERIMENTAL
Intervention: Frequent hand washing (7-10 times/day)
Number of subjects: 6273

Group type: EXPERIMENTAL
Intervention: Frequent hand washing (>10 times/day)
Number of subjects: 6273

Group type: EXPERIMENTAL
Intervention: No prior symptoms of dermatitis
Number of subjects: 6273

Group type: EXPERIMENTAL
Intervention: Schoolchildren
Number of subjects: 6273

Group type: COMPARATOR
Intervention: Alcohol-based hand sanitiser
Number of subjects: 6273
Study: 32800381

Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine 20 mg/d
Number of subjects: 219
Study: 32800503

Group type: EXPERIMENTAL
Intervention: General anaesthesia with sevoflurane
Number of subjects: 72
Study: 32800518

Group type: EXPERIMENTAL
Intervention: Tositumomab (TST) and iodine-131 tositumomab (I-131 TST) followed by CHOP treatment
Number of subjects: 26
Study: 32800660

Group type: EXPERIMENTAL
Intervention: EndoAVF
Number of subjects: 123
Study: 32800708

Group type: EXPERIMENTAL
Intervention: Intravenous antimicrobial exacerbation treatments
Number of subjects: 173
Study: 32800759

Group type: EXPERIMENTAL
Intervention: Summer diet quality
Number of subjects: 62
Study: 32800802

Group type: EXPERIMENTAL
Intervention: Definitive (chemo)radiation therapy for HPV-related OPC
Number of subjects: 62
Study: 32801008

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) concentration
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Prediction model for week 52 histologic remission
Number of subjects: 639
Study: 32801120

Group type: EXPERIMENTAL
Intervention: mtDNA-CN (10th vs 90th percentile) among black participants
Number of subjects: 11398

Group type: EXPERIMENTAL
Intervention: mtDNA-CN (10th vs 90th percentile) among white participants
Number of subjects: 11398
Study: 32801129

Group type: EXPERIMENTAL
Intervention: Adding GA to HbA
Number of subjects: 0
Study: 32801139

Group type: EXPERIMENTAL
Intervention: Metagenome sequencing and 16S rRNA sequencing technologies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spearman analysis
Number of subjects: 0
Study: 32801289

Group type: EXPERIMENTAL
Intervention: 7-day Holter monitoring
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Serum brain natriuretic peptide ≥ 66.0 pg/mL
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Atrial premature contractions (APCs) ≥ 345 beats
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: APC short runs ≥ 13
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Validation cohort results for serum brain natriuretic peptide
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Validation cohort results for APC count
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Validation cohort results for APC short runs
Number of subjects: 206
Study: 32802051

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (bolus dose over 15 min after delivery for parturient group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexmedetomidine (bolus administered intravenously upon completion of spinal anesthesia for nonpregnant women group)
Number of subjects: 60
Study: 32802114

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham Electroacupuncture
Number of subjects: 30
Study: 32802401

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/day, vitamin D 2000 IU/day, GAD-alum 20 μg on D15 and D45
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo instead of Ibuprofen, vitamin D 2000 IU/day, GAD-alum 20 μg on D15 and D45
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/day, vitamin D 2000 IU/day, GAD-alum 40 μg on D15 and D45
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo instead of Ibuprofen, vitamin D 2000 IU/day, GAD-alum 40 μg on D15 and D45
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ibuprofen, vitamin D + GAD-alum
Number of subjects: 64
Study: 32802883

Group type: EXPERIMENTAL
Intervention: Mon2 cell fraction and Mon2 expression of CX3CR1, CD18, and CD16 in CAD2 and CAD3 groups
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Total monocyte population
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mon2 expression of CD16
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: TNF-
Number of subjects: 73
Study: 32803165

Group type: EXPERIMENTAL
Intervention: Radioembolization
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI (including IVIM DWI and gadoxetic acid DCE MRI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pretreatment DCE MRI histogram parameters
Number of subjects: 24
Study: 32803573

Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab
Number of subjects: 54
Study: 32803633

Group type: EXPERIMENTAL
Intervention: Vantictumab plus weekly paclitaxel 90 mg/m
Number of subjects: 48
Study: 32803882

Group type: EXPERIMENTAL
Intervention: More intensive insulin therapy
Number of subjects: 603

Group type: COMPARATOR
Intervention: Dipeptidyl peptidase-4 (DPP-4) inhibitors
Number of subjects: 603

Group type: COMPARATOR
Intervention: Sodium glucose co-transporter 2 (SGLT2) inhibitors
Number of subjects: 603

Group type: COMPARATOR
Intervention: Glitazones
Number of subjects: 603
Study: 32803990

Group type: EXPERIMENTAL
Intervention: Plasma Tenascin-C in HFpEF
Number of subjects: 172

Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 172
Study: 32804069

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Hypersomnia (CBT-H)
Number of subjects: 35
Study: 32804087

Group type: EXPERIMENTAL
Intervention: Keyto mHealth app and device intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Weight Watchers' WW app
Number of subjects: 144
Study: 32804088

Group type: EXPERIMENTAL
Intervention: Health education and periodic mobile phone-based text message intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 420
Study: 32804101

Group type: EXPERIMENTAL
Intervention: Pimavanserin (monotherapy or adjunctive therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pimavanserin (monotherapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pimavanserin (adjunctive therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 45
Study: 32804326

Group type: EXPERIMENTAL
Intervention: BDNF Val66Met carriers
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: APOE-ε4 homozygous BDNF Met carriers
Number of subjects: 430

Group type: COMPARATOR
Intervention: APOE-ε4 allele
Number of subjects: 430
Study: 32804590

Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg once daily (n = 142)
Number of subjects: 258
Study: 32804785

Group type: EXPERIMENTAL
Intervention: Endotracheal tube size ≤ 7.5
Number of subjects: 210

Group type: COMPARATOR
Intervention: Endotracheal tube size ≥ 8.0
Number of subjects: 210
Study: 32805151

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 1633
Study: 32805208

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (52 mg levonorgestrel, Mirena)
Number of subjects: 57
Study: 32805238

Group type: EXPERIMENTAL
Intervention: Reverse Triggering (RT) detected in patients receiving assist-control ventilation for mild or moderate ARDS.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presence of RT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RT detection
Number of subjects: 100
Study: 32805273

Group type: EXPERIMENTAL
Intervention: FAZA PET/CT imaging with a hypoxia threshold determined by a tumor-to-muscle ratio (TMR) of 1.6
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with more hypoxic, non-OPCp16+ tumors (TMR ≥1.6)
Number of subjects: 38
Study: 32806876

Group type: EXPERIMENTAL
Intervention: vedolizumab 108 mg SC every 2 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: vedolizumab 300 mg IV every 8 weeks
Number of subjects: 49
Study: 32807084

Group type: EXPERIMENTAL
Intervention: $50 cash card requiring email activation
Number of subjects: 501

Group type: COMPARATOR
Intervention: Checks
Number of subjects: 501
Study: 32807090

Group type: EXPERIMENTAL
Intervention: nvHAP prevention bundle consisting of oral care, prevention of dysphagia-related aspiration, mobilization, stopping unnecessary proton pump inhibitors, and respiratory therapy.
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: nvHAP prevention bundle implementation strategy including education, training, and environmental restructuring.
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Qualitative study based on interviews, focus groups, and observations.
Number of subjects: 950
Study: 32807203

Group type: EXPERIMENTAL
Intervention: High pericardial fat
Number of subjects: 254
Study: 32807456

Group type: EXPERIMENTAL
Intervention: Cryptogenic ischemic stroke patients
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Patients with RIS
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Obesity and previous use of antiplatelet therapy
Number of subjects: 208
Study: 32807703

Group type: EXPERIMENTAL
Intervention: Combined stress myocardial CT perfusion (CTP) with coronary CT angiography (CTA)
Number of subjects: 145

Group type: COMPARATOR
Intervention: SPECT myocardial perfusion imaging (SPECT-MPI)
Number of subjects: 145
Study: 32807717

Group type: EXPERIMENTAL
Intervention: High-dose weekly carfilzomib, cyclophosphamide, and dexamethasone
Number of subjects: 3
Study: 32808077

Group type: EXPERIMENTAL
Intervention: Consensus reads
Number of subjects: 217
Study: 32808163

Group type: EXPERIMENTAL
Intervention: Ivabradine 2.5-7.5 mg twice daily for 57 days
Number of subjects: 30
Study: 32808208

Group type: EXPERIMENTAL
Intervention: Practice facilitation and health information technology support for 9 months, plus biannual collaborative learning sessions
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Use of cardiovascular disease registries, standing orders, or electronic health record prompts
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Implementation of building blocks of high-performing primary care
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Team-based care and population management
Number of subjects: 211
Study: 32808556

Group type: EXPERIMENTAL
Intervention: pegylated IL-10/nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32808833

Group type: EXPERIMENTAL
Intervention: Endocan levels measured in women with idiopathic POI
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 38
Study: 32808936

Group type: EXPERIMENTAL
Intervention: REDCHiP intervention (video-based telehealth intervention)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Attention control intervention
Number of subjects: 180
Study: 32809030

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST) at low frequency (25 Hz)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST) at moderate frequency (50 or 60 Hz)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST) at high frequency (100 Hz)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall MST treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Beck Scale for Suicidal Ideation scores
Number of subjects: 67
Study: 32809083

Group type: EXPERIMENTAL
Intervention: 3D printed brace for acute treatment of DRF
Number of subjects: 5
Study: 32809217

Group type: EXPERIMENTAL
Intervention: MK-1248 monotherapy (starting dose 0.12 mg, maximum dose 170 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MK-1248 with pembrolizumab (200 mg) combination therapy (maximum dose 60 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 37
Study: 32809873

Group type: EXPERIMENTAL
Intervention: Cardiac autonomic control system (CACS) assessment in adolescents post-TBI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vestibular/oculomotor system assessment in adolescents post-TBI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interaction between CACS and vestibular/oculomotor systems during position change
Number of subjects: 0
Study: 32809896

Group type: EXPERIMENTAL
Intervention: Remote learning intervention (hybrid of self-study and hands-on practice with remote feedback) for ten manual wheelchair skills.
Number of subjects: 41
Study: 32809969

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg twice daily for 2 days, followed by 4 mg per day for 7 days
Number of subjects: 20
Study: 32810906

Group type: EXPERIMENTAL
Intervention: PROMIS-10 physical health assessment
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: PROMIS-10 mental health assessment
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: PHQ-4 assessment for depression or anxiety
Number of subjects: 1064
Study: 32811386

Group type: EXPERIMENTAL
Intervention: Transcarotid artery revascularization (TCAR)
Number of subjects: 632
Study: 32811390

Group type: EXPERIMENTAL
Intervention: Cardioembolic thrombi
Number of subjects: 250

Group type: COMPARATOR
Intervention: Noncardioembolic thrombi
Number of subjects: 250
Study: 32811463

Group type: EXPERIMENTAL
Intervention: Monocyte-to-lymphocyte ratio (MLR)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Platelet-to-lymphocyte ratio (PLR)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Red blood cell count
Number of subjects: 145
Study: 32811969

Group type: EXPERIMENTAL
Intervention: Tocilizumab in combination with methotrexate
Number of subjects: 485
Study: 32812370

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 377
Study: 32812804

Group type: EXPERIMENTAL
Intervention: De novo damaging variants
Number of subjects: 2517

Group type: EXPERIMENTAL
Intervention: De novo variants
Number of subjects: 2517
Study: 32812818

Group type: EXPERIMENTAL
Intervention: Midostaurin plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 32812942

Group type: EXPERIMENTAL
Intervention: 30-g rapidly-digesting carbohydrate (RDC) drink consisting of maltodextrin and sucrose, administered after an 8-h fast.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Controlled diet provided for three days prior to the breath tests.
Number of subjects: 19
Study: 32813194

Group type: EXPERIMENTAL
Intervention: PR-PFD (600 mg bid)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: PR-PFD
Number of subjects: 281
Study: 32813272

Group type: EXPERIMENTAL
Intervention: Aromatherapy (lavender, lemon balm, cedar extracts, etc.)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 708
Study: 32813276

Group type: EXPERIMENTAL
Intervention: TCCMD (Targeted client communication via mobile devices)
Number of subjects: 17463

Group type: EXPERIMENTAL
Intervention: TCCMD
Number of subjects: 17463
Study: 32813609

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32813873

Group type: EXPERIMENTAL
Intervention: Abatacept with tacrolimus and methotrexate as GVHD prophylaxis
Number of subjects: 14
Study: 32813874

Group type: EXPERIMENTAL
Intervention: Myeloablative haploBMT with posttransplantation cyclophosphamide (PTCy)
Number of subjects: 96
Study: 32813884

Group type: COMPARATOR
Intervention: Stem cell-based interventions (any type)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mesenchymal stem/stromal cells (MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other stem cell-based interventions (e.g. mononuclear cells, oligodendrocyte progenitor cells, neural stem cells, hematopoietic stem cells, and inducible pluripotent stem cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MSCs
Number of subjects: 0
Study: 32813948

Group type: EXPERIMENTAL
Intervention: Diet group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surgery group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study: 32814420

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 462
Study: 32814465

Group type: EXPERIMENTAL
Intervention: Device-detected atrial arrhythmias (AAs) during follow-up
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clinically significant AA burden after treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Initial presentation of AAs
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: AA burden after treatment
Number of subjects: 33
Study: 32814553

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy, native tissue cystocele and rectocele repair, bilateral sacrospinous vaginal fixation
Number of subjects: 20
Study: 32814852

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chocolate Milk
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sitting (Control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 20
Study: 32814997

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (Q4W)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (Q2W)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Ixekizumab (Q2W) in TNFi-experienced patients
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo (initially for some patients)
Number of subjects: 656
Study: 32815611

Group type: EXPERIMENTAL
Intervention: Echo-focusing (EF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CT-based aberration corrections
Number of subjects: 12
Study: 32815870

Group type: EXPERIMENTAL
Intervention: rifapentine plus isoniazid
Number of subjects: 128
Study: 32815872

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pulse oximetry hemoglobin saturation (Spo2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Difference in warning times (ORI - Spo2)
Number of subjects: 40
Study: 32815890

Group type: EXPERIMENTAL
Intervention: Dynamic gait stability
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hip extensor strength
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) score
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall fall risk prediction model
Number of subjects: 56
Study: 32816326

Group type: EXPERIMENTAL
Intervention: Real-time quantitative polymerase chain reaction (RQ-PCR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Digital-droplet PCR (ddPCR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Immunoglobulin kappa-deleting-element (IGK-Kde) rearrangements
Number of subjects: 37
Study: 32816519

Group type: EXPERIMENTAL
Intervention: Nonacog gamma (BAX 326, Rixubis)
Number of subjects: 0
Study: 32816630

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + bevacizumab
Number of subjects: 1697

Group type: COMPARATOR
Intervention: doublets + bevacizumab
Number of subjects: 1697
Study: 32816721

Group type: EXPERIMENTAL
Intervention: Oxfendazole oral suspension at 3, 7.5, and 15 mg/kg once daily for 5 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single 3 mg/kg dose of oxfendazole after overnight fast
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single 3 mg/kg dose of oxfendazole after consumption of a fatty breakfast
Number of subjects: 36
Study: 32816723

Group type: EXPERIMENTAL
Intervention: Fluconazole treatment, dosage not specified, duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32816724

Group type: EXPERIMENTAL
Intervention: Caspofungin in ECMO patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Caspofungin in non-ECMO patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Caspofungin before ECMO weaning
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Caspofungin after ECMO weaning
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 19
Study: 32816849

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockade
Number of subjects: 0
Study: 32816891

Group type: EXPERIMENTAL
Intervention: Tebentafusp
Number of subjects: 84
Study: 32816893

Group type: EXPERIMENTAL
Intervention: AA patients
Number of subjects: 331

Group type: COMPARATOR
Intervention: Non-AA cohort
Number of subjects: 331
Study: 32816892

Group type: EXPERIMENTAL
Intervention: Vocimagene amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC)
Number of subjects: 0
Study: 32816951

Group type: EXPERIMENTAL
Intervention: MEDI0562 (0.03, 0.1, 0.3, 1.0, 3.0, or 10 mg/kg) administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MEDI0562 (0.03, 0.1, 0.3, 1.0, 3.0, or 10 mg/kg) administered intravenously every 2 weeks.
Number of subjects: 55
Study: 32816955

Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (EFTR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard endoscopic resection (SER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled alternative treatment to EFTR
Number of subjects: 0
Study: 32817006

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 0
Study: 32817060

Group type: EXPERIMENTAL
Intervention: CDKi as first-line treatment
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: CDKi as second-line treatment
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: CDKi as third-line treatment and beyond
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: CDKi treatment
Number of subjects: 365
Study: 32817079

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 38
Study: 32817288

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg, two weeks apart) combined with belimumab (10 mg/kg at week 0, W0+2 days, W2+2 days, W4, W8, and W12)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rituximab alone (comparison group)
Number of subjects: 15
Study: 32817460

Group type: EXPERIMENTAL
Intervention: Elevated serum LIGHT levels in hospitalized COVID-19 patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients on and off ventilatory support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients over the age of 60
Number of subjects: 0